Abbas F, Scardino P T
Matsunaga-Conte Prostate Cancer Research Center, Baylor College of Medicine, Houston, Texas, USA.
Urol Clin North Am. 1996 Nov;23(4):587-604. doi: 10.1016/s0094-0143(05)70338-4.
Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy has been advocated for downstaging of tumors and reducing the rates of positive surgical margins with the expectation that disease-free survival will be improved. Despite the apparent favorable impact on pathologic findings, randomized trials to date show no benefit of NHT in prostate-specific antigen progression rates. Consequently, there is serious concern about the validity and biologic significance of the apparent downstaging and decreased rate of positive margins, and no evidence exists that there is improved time to progression and survival; therefore, the authors do not recommend NHT outside of a clinical trial.
根治性前列腺切除术之前的新辅助激素治疗（NHT）已被提倡用于肿瘤降期和降低手术切缘阳性率，期望能改善无病生存期。尽管对病理结果有明显的有利影响，但迄今为止的随机试验表明，NHT在前列腺特异性抗原进展率方面并无益处。因此，人们严重质疑明显的降期和切缘阳性率降低的有效性和生物学意义，且没有证据表明疾病进展时间和生存期得到改善；所以，作者不建议在临床试验之外使用NHT。
